640 IBD patients completed the conjoint analysis.³⁹ The Figure below shows which biologic attributes drove biologic decision-making for those with ulcerative colitis (UC) and Crohn’s disease (CD). On average, the highest priority for UC patients when deciding among the different biologics was long-term remission rates. They also highly weighted mode of administration, lymphoma risk, and short-term improvement rates. CD patients, on the other hand, most prioritized short-term improvement rates as they were choosing a biologic. Lymphoma risk, mode of administration, and long-term remission rates were key factors in their decision-making processes as well. This suggests that UC and CD patients approach biologic decision-making in a different manner.